Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET. During the event, CEO Brad Hauser will provide a corporate overview and discuss the company's innovative catheter-based microchip sensing array technology. This first-in-class platform system aims to enhance neural signal detection and differentiation compared to existing technologies.
The event will include a live interactive Q&A session where investors can submit questions. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days following the event.
Autonomix Medical (NASDAQ: AMIX) ha annunciato la sua partecipazione alla serie Virtual Investor Closing Bell, prevista per il 22 maggio 2025 alle 16:00 ET. Durante l'evento, l'amministratore delegato Brad Hauser fornirà una panoramica aziendale e illustrerà la tecnologia innovativa basata su catetere con matrice di microchip sensoriale dell'azienda. Questo sistema di piattaforma unico nel suo genere mira a migliorare la rilevazione e la differenziazione dei segnali neurali rispetto alle tecnologie attualmente disponibili.
L'evento comprenderà una sessione di domande e risposte interattiva in diretta, durante la quale gli investitori potranno inviare le loro domande. La presentazione sarà accessibile tramite una diretta video webcast sul sito web dell'azienda, con una replica disponibile per 90 giorni dopo l'evento.
Autonomix Medical (NASDAQ: AMIX) anunció su participación en la serie Virtual Investor Closing Bell programada para el 22 de mayo de 2025 a las 4:00 PM ET. Durante el evento, el CEO Brad Hauser ofrecerá una visión general de la empresa y hablará sobre la innovadora tecnología basada en un arreglo de microchips sensoriales mediante catéter. Este sistema de plataforma pionero busca mejorar la detección y diferenciación de señales neuronales en comparación con las tecnologías existentes.
El evento incluirá una sesión interactiva de preguntas y respuestas en vivo, donde los inversores podrán enviar sus preguntas. La presentación será accesible a través de una transmisión en vivo por video en el sitio web de la compañía, con una repetición disponible durante 90 días posteriores al evento.
Autonomix Medical (NASDAQ: AMIX)는 2025년 5월 22일 오후 4시(동부 시간)에 예정된 Virtual Investor Closing Bell 시리즈에 참여한다고 발표했습니다. 행사 중 CEO 브래드 하우저가 회사 개요를 제공하고 혁신적인 카테터 기반 마이크로칩 센싱 배열 기술에 대해 설명할 예정입니다. 이 독창적인 플랫폼 시스템은 기존 기술에 비해 신경 신호의 감지 및 구분 능력을 향상시키는 것을 목표로 합니다.
이벤트에는 투자자들이 질문을 제출할 수 있는 실시간 인터랙티브 Q&A 세션이 포함됩니다. 발표는 회사 웹사이트에서 라이브 비디오 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 다시보기 서비스도 제공됩니다.
Autonomix Medical (NASDAQ : AMIX) a annoncé sa participation à la série Virtual Investor Closing Bell prévue le 22 mai 2025 à 16h00 ET. Lors de cet événement, le PDG Brad Hauser présentera un aperçu de l'entreprise et discutera de la technologie innovante basée sur un réseau de micro-puces à cathéter. Ce système de plateforme unique en son genre vise à améliorer la détection et la différenciation des signaux neuronaux par rapport aux technologies existantes.
L'événement comprendra une session interactive de questions-réponses en direct, permettant aux investisseurs de soumettre leurs questions. La présentation sera accessible via une webdiffusion vidéo en direct sur le site web de la société, avec un replay disponible pendant 90 jours après l'événement.
Autonomix Medical (NASDAQ: AMIX) gab seine Teilnahme an der Virtual Investor Closing Bell Series bekannt, die für den 22. Mai 2025 um 16:00 Uhr ET geplant ist. Während der Veranstaltung wird CEO Brad Hauser einen Unternehmensüberblick geben und die innovative katheterbasierte Mikrochip-Sensorarray-Technologie des Unternehmens vorstellen. Dieses erstklassige Plattform-System zielt darauf ab, die Erkennung und Unterscheidung neuronaler Signale im Vergleich zu bestehenden Technologien zu verbessern.
Die Veranstaltung umfasst eine interaktive Live-Fragerunde, bei der Investoren Fragen stellen können. Die Präsentation wird über einen Live-Video-Webcast auf der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET
Access the event here
THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
(908) 824-0775
autonomix@jtcir.com
FAQ
When is Autonomix Medical (AMIX) presenting at the Virtual Investor Closing Bell Event?
What technology will AMIX CEO Brad Hauser discuss during the presentation?
How can investors access the AMIX Virtual Investor Closing Bell presentation?
How long will the AMIX presentation replay be available?
